ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Spero Therapeutics Inc

Spero Therapeutics Inc (SPRO)

0.874
-0.0216
(-2.41%)
Cerrado 22 Enero 3:00PM
0.898
0.024
(2.75%)
Fuera de horario: 4:55PM

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
0.898
Postura de Compra
0.86
Postura de Venta
0.92
Volume Operado de la Acción
184,476
0.859 Rango del Día 0.9399
0.83 Rango de 52 semanas 1.89
Capitalización de Mercado [m]
Precio Anterior
0.8956
Precio de Apertura
0.89
Última hora de negociación
Volumen financiero
US$ 163,323
Precio Promedio Ponderado
0.885334
Volumen promedio (3 m)
317,722
Acciones en circulación
54,518,165
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
2.08
Beneficio por acción (BPA)
0.42
turnover
103.78M
Beneficio neto
22.81M

Acerca de Spero Therapeutics Inc

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is de... Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sede
Wilmington, Delaware, USA
Fundado
-
Spero Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SPRO. The last closing price for Spero Therapeutics was US$0.90. Over the last year, Spero Therapeutics shares have traded in a share price range of US$ 0.83 to US$ 1.89.

Spero Therapeutics currently has 54,518,165 shares in issue. The market capitalisation of Spero Therapeutics is US$48.83 million. Spero Therapeutics has a price to earnings ratio (PE ratio) of 2.08.

SPRO Últimas noticias

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company’s Response to a Wells Notice...

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov. 14...

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...

Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update

Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary endpoint, based on planned interim analysis of 16...

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with standard of care agents Study highlighting...

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

CAMBRIDGE, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.052-5.473684210530.950.9740.834467330.88013884CS
4-0.042-4.468085106380.941.130.832842270.95989874CS
12-0.142-13.65384615381.041.340.833177221.12597305CS
26-0.522-36.76056338031.421.470.832153151.18847211CS
52-0.502-35.85714285711.41.890.832276691.39783867CS
156-10.322-91.996434937611.2212.17630.68019813911.8690176CS
260-8.242-90.17505470469.1423.6390.68016639303.37067758CS

SPRO - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Spero Therapeutics?
El precio actual de las acciones de Spero Therapeutics es US$ 0.898
¿Cuántas acciones de Spero Therapeutics están en circulación?
Spero Therapeutics tiene 54,518,165 acciones en circulación
¿Cuál es la capitalización de mercado de Spero Therapeutics?
La capitalización de mercado de Spero Therapeutics es USD 48.83M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Spero Therapeutics?
Spero Therapeutics ha negociado en un rango de US$ 0.83 a US$ 1.89 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Spero Therapeutics?
El ratio precio/beneficio de Spero Therapeutics es 2.08
¿Cuál es el ratio de efectivo a ventas de Spero Therapeutics?
El ratio de efectivo a ventas de Spero Therapeutics es 0.46
¿Cuál es la moneda de reporte de Spero Therapeutics?
Spero Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Spero Therapeutics?
El último ingresos anual de Spero Therapeutics es USD 103.78M
¿Cuál es el último beneficio anual de Spero Therapeutics?
El último beneficio anual de Spero Therapeutics es USD 22.81M
¿Cuál es la dirección registrada de Spero Therapeutics?
La dirección registrada de Spero Therapeutics es CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Spero Therapeutics?
La dirección del sitio web de Spero Therapeutics es www.sperotherapeutics.com
¿En qué sector industrial opera Spero Therapeutics?
Spero Therapeutics opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
BLBXBlackBoxStocks Inc
US$ 5.53
(227.22%)
229.07M
ASSTAsset Entities Inc
US$ 1.36
(51.11%)
121.67M
STAIScanTech AI Systems Inc
US$ 2.12
(44.22%)
51.68M
JYDJayud Global Logistics Ltd
US$ 3.53
(42.91%)
1.27M
NTRBNutriband Inc
US$ 7.39
(41.84%)
3.88M
STFSStar Fashion Culture Holdings Ltd
US$ 2.62
(-80.61%)
30.25M
HEPAHepion Pharmaceuticals Inc
US$ 0.135
(-58.05%)
39.89M
STBXStarBox Group Holdings Ltd
US$ 0.6201
(-36.50%)
1.63M
WHLRLWheeler Real Estate Investment Trust Inc
US$ 93.51
(-35.73%)
1
JUNSJupiter Neurosciences Inc
US$ 3.61
(-33.39%)
6.87M
IPAImmunoPrecise Antibodies Ltd
US$ 0.6446
(30.75%)
296.43M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.3191
(33.57%)
229.11M
BLBXBlackBoxStocks Inc
US$ 5.53
(227.22%)
229.08M
NVDANVIDIA Corporation
US$ 147.07
(4.43%)
216.62M
RGTIRigetti Computing Inc
US$ 13.89
(-0.64%)
154.54M

SPRO Discussion

Ver más
Monksdream Monksdream 5 meses hace
SPRO under $2
👍️0
Monksdream Monksdream 6 meses hace
SPRO under $2
👍️0
Monksdream Monksdream 9 meses hace
SPRO under $2
👍️0
Monksdream Monksdream 10 meses hace
SPRO under $2
👍️0
glenn1919 glenn1919 10 meses hace
SPRO...................................https://stockcharts.com/h-sc/ui?s=SPRO&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 10 meses hace
SPRO 10Q due March 13
👍️0
Monksdream Monksdream 11 meses hace
SPRO under $2
👍️0
Monksdream Monksdream 1 año hace
SPRO new 52 week low
👍️0
Monksdream Monksdream 1 año hace
SPRO new 52 week low
👍️0
Monksdream Monksdream 1 año hace
SPRO new 52 week low
👍️0
Monksdream Monksdream 1 año hace
SPRO under $2
👍️0
Awl416 Awl416 1 año hace
News?
👍️0
m0n m0n 1 año hace
$SPRO YuuuuGE FDA News

Spero Therapeutics shares were up 14% at $1.62 after the company received written agreement from the U.S. Food and
Drug Administration, under a Special Protocol Assessment, on the design and size of its pivotal Phase 3 clinical trial
of tebipenem HBr in patients with complicated urinary tract infection, including acute pyelonephritis.
👍️0
81vette 81vette 2 años hace
Urinary tract infection drug,$66m reviewed up to 525m coming,royalties on sales is astronomical
👍️0
81vette 81vette 2 años hace
Pfizer paid $5m of $40 and $80m total coming for license agreement,many more deals coming ,some phase 3 trials near done OMG THE BIG DEALS COMING
👍️0
81vette 81vette 2 años hace
Look at the candle on this chart 6 month record high,now look back to see what happens with big vol
👍️0
81vette 81vette 2 años hace
Look at the candle on this chart 6 month record high,now look back to see what happens with big vol
👍️0
81vette 81vette 2 años hace
Relative vol up 28Xs ,buy vol up 1000s% I AM FOLLOWING THE $ ppl with big $ know something huge coming
👍️0
81vette 81vette 2 años hace
Relative vol up 28Xs ,buy vol up 1000s% I AM FOLLOWING THE $ ppl with big $ know something huge coming
👍️0
saigai saigai 2 años hace
ive had some strange experiences with stocks but this one has me baffled but not beaten..
👍️0
saigai saigai 2 años hace
someone just unloaded a boat load and or shorted same. halfway around the cape and battered by high winds but not going anywhere. i cant
👍️0
saigai saigai 2 años hace
they will short this back down to .80 at this rate . eff me
👍️0
saigai saigai 2 años hace
folks keep walking away.. day after day after day.. ill be here im lashed to the mast of this bark as we get blistered around the cape
👍️0
saigai saigai 2 años hace
damn heavy unloading
👍️0
saigai saigai 2 años hace
big volume crashing again.. and i thought i was smart.. hahahahahastill bullish
👍️0
saigai saigai 2 años hace
must be some kind of inside news. this keeps falling and i dont get it.. but too late now .. this is the hill i die on or
👍️0
saigai saigai 2 años hace
a little retail short covering for the green. ill take it
👍️0
saigai saigai 2 años hace
another day of heavy downside volume in the cards..not good
👍️0
saigai saigai 2 años hace
shorts in control
👍️0
StockLogistics StockLogistics 2 años hace
GSK believed in SPRO enough to pay over 60 million at once, when investors get the same belief level it would in theory skyrocket, risk/reward and forward expectations are supposed to partially drive share price along with cash available to reduce risk of dilution, cash which GSK provided.
👍️0
StockLogistics StockLogistics 2 años hace
GSK believed in SPRO enough to pay over 60 million at once, when investors get the same belief level it would in theory skyrocket, risk/reward and forward expectations are supposed to partially drive share price along with cash available to reduce risk of dilution, cash which GSK provided.
👍️0
saigai saigai 2 años hace
a little run into earnings. ill hold through it and beyond
👍️0
saigai saigai 2 años hace
https://finance.yahoo.com/news/spero-therapeutics-announces-closing-exclusive-130500913.html
👍️0
saigai saigai 2 años hace
maybe we get some interest from this
https://finance.yahoo.com/news/spero-therapeutics-inc-spro-expected-140102871.html
👍️0
saigai saigai 2 años hace
ill be here when the mkt cap is over a billion
👍️0
saigai saigai 2 años hace
https://finance.yahoo.com/news/spero-therapeutics-present-data-idweek-120500461.html
👍️0
saigai saigai 2 años hace
almost no pre opening trading...the waters have stilled.. it wont stay calm for long ..lets see which way it breaks
👍️0
saigai saigai 2 años hace
bought more i wont be bought off with impatience
👍️0
saigai saigai 2 años hace
enter the flipper
👍️0
saigai saigai 2 años hace
just when you have given up hope a volume burst and a price pop
👍️0
StockLogistics StockLogistics 2 años hace
Macd on one month about to cross lower unless they have premarket news, many will sell premarket without news so if they have something releasing it premarket would be best for loyal shareholders who would miss out on a new release later in the session.
👍️0
saigai saigai 2 años hace
ugly ugly day again....but in a sane world this is 10x the mkt cap it is today
👍️0
saigai saigai 2 años hace
grinding our way to fair value.. whatever that is well north of here
👍️0
saigai saigai 2 años hace
hopefully we hold these gains
👍️0
StockLogistics StockLogistics 2 años hace
“8:05a ET 10/3/2022 - Globe Newswire
Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program

GlobeNewswireOctober 03, 2022
Event is taking place on Thursday, October 6th at 11:30 a.m. ET


Event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH (Division of Infectious Disease, OHSU Medical School)

CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a virtual R&D event on Thursday, October 6, 2022, at 11:30 a.m. Eastern Time.

The virtual event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH, from the Division of Infectious Disease, OHSU Medical School. During his presentation, Dr. Winthrop will discuss the etiology, unmet medical need, and treatment landscape of non-tuberculous mycobacteria (NTM) pulmonary disease. Members of the Spero management team will provide an overview of the development program for SPR720, a potential novel first line oral therapy for NTM infections.

A live Q&A session will follow the formal presentations. To register for the event, please click here.

Dr. Winthrop Biography:

Kevin L. Winthrop, MD, MPH, Professor of Public Health, Infectious Diseases, and Ophthalmology at Oregon Health and Science University, is a former staff infectious disease epidemiologist from the U.S. Centers for Disease Control and Prevention's Division of Tuberculosis Elimination. He has co-authored over 300 publications, many detailing the epidemiologic and clinical aspects of nontuberculous mycobacterial diseases, tuberculosis, and other infections associated with rheumatic diseases and biologic immunosuppressive therapies. Clinically, he provides regional consultations for mycobacterial diseases and other chronic chest infections and serves as the medical consultant to the Oregon Public Health Division's TB control program. His Center for Infectious Disease Studies has served as the lead institution and coordinating center for multiple cohort studies and clinical trials. He has served as a primary or senior investigator in many of these clinical and epidemiologic studies, and frequently collaborates with the Pulmonary Department on studies related to bronchiectasis. He founded the NTM Research Consortium and associated Clinical Trials Network which facilitate collaborative, multi-site grants and clinical trials among patients with NTM. He is a member of the graduate faculty at OHSU where he mentors public health students, medical students, and physicians in post-graduate training.”
👍️0
saigai saigai 2 años hace
look out above...lets go friday
👍️0
StockLogistics StockLogistics 2 años hace
“If Spero’s license with Meiji is terminated, or if Meiji forfeits or loses its rights to develop, manufacture and commercialize tebipenem HBr and products that contain tebipenem HBr in any countries in the Meiji Territory, then GSK will have an exclusive first right to negotiate with Spero to add any such countries to the GSK Territory.
Under the terms of the License Agreement, Spero will receive an upfront payment of $66 million for GSK to secure rights to the medicine. Remaining potential payments are milestone based, and are as follows:

Event Milestone payments (up to)
Delivery of phase III programme
$150m
Total commercial milestone payments based on first sale (US/EU)
$150m
Sales milestone events

Net sales greater than $200m
$25m
Net sales greater than $300m
$25m
Net sales greater than $400m
$25m
Net sales greater than $500m
$50m
Net sales greater than $750m
$50m
Net sales greater than $1,000m
$50m
Total sales milestone payments:
$225m
Royalties
Low-single digit to low-double digit (if
sales exceed $1bn) tiered royalties
on net product sales.
Royalties are subject to reduction in the event of third-party licenses, entry of a generic product or expiration of patent and regulatory exclusivity prior to the tenth (10th) anniversary of the first commercial sale of a GSK Licensed Product in a particular country.
Spero will be responsible for the execution and costs of the follow-up Phase III clinical trial of tebipenem HBr. GSK will be responsible for the execution and costs of additional further development, including Phase III regulatory filing and commercialization activities for tebipenem HBr in the balance of the GSK Territory outside of the United States. Spero will also be responsible for providing and paying for the clinical supply of tebipenem HBr while GSK will be responsible for the costs of the commercial supply of tebipenem HBr. A joint development committee will be established between GSK and Spero to coordinate and review development activities for tebipenem HBr in the United States.”
👍️0
saigai saigai 2 años hace
a few smart shorts see the writing on the wall..and nd it just takes time to consolidate through the profits through the shorting through the day flippers and the criminals..takes time
👍️0
saigai saigai 2 años hace
red to green when you least expect it
👍️0
SmokeSignals SmokeSignals 2 años hace
start loading for $5 imo
👍️0

Su Consulta Reciente

Delayed Upgrade Clock